

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Highly Specialised Technology

Birch bark extract for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa [ID1505]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Amryt Pharma (birch bark extract) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Beacon Changing Faces Contact DEBRA UK Gene People Genetic Alliance UK Let's Face It South Asian Health Foundation Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Genetic Nurses & Counsellors Association of Paediatric Emergency Medicines British Association for Immediate Care British Association of Dermatologists British Dermatological Nursing Group British Geriatrics Society British Society for Cutaneous Allergy British Society for Gene and Cell Therapy <p><u>Therapy</u></p> <ul style="list-style-type: none"> British Society for Genetic Medicine British Trauma Society National Diagnostic Epidermolysis Bullosa Laboratory Neonatal and Paediatric Pharmacists Group Primary Care Dermatology Society Royal College of Emergency Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Cell and Gene Therapy Catapult Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association National Services Division (specialised services in Scotland) NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> British Epidermo-Epidemiology Society British Skin Foundation Centre of Evidence-based Dermatology, University of Nottingham

Final stakeholder list for the highly specialised technology evaluation for birch bark extract for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa [ID1505]. Issue Date: August 2022

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society of Tissue Viability • St John's Institute of Dermatology • Surgical Dressing Manufacturers Association • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Skin Group • Cochrane UK • Cochrane Wounds Group • Cure EB • Genetic Skin Disease Group, King's College London • Genomics England • Health Services Research Unit, Department of Public Health, University of Oxford • MRC Clinical Trials Unit • National Institute for Health & Care Research • Skin Treatment & Research Trust • Wounds UK <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.